# A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

> **NCT01218516** · PHASE2 · COMPLETED · sponsor: **Morphotek** · enrollment: 130 (actual)

## Conditions studied

- Adenocarcinoma of the Lung

## Interventions

- **BIOLOGICAL:** Farletuzumab
- **OTHER:** Placebo
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01218516
- **Lead sponsor:** Morphotek
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-27
- **Primary completion:** 2012-12-15
- **Final completion:** 2013-11-01
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2020-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218516, "A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01218516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*